Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations

NCT02728258 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT02728258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02728258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Lead sponsor
NRG Oncology
Phase
Phase 2
Overall status
Completed
Start date
September 16, 2016
Completion date
February 14, 2020
Enrollment
11 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial endometrioid adenocarcinoma, endometrial mixed cell adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, metastatic endometrioid adenocarcinoma, recurrent uterine corpus cancer